Phase i study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 1083-1094

  Chen, Nianhang ^a   Chawla, Sant P ^b   Chiorean, Elena Gabriela ^c   Read, William L ^d   Gorbaty, Mayer ^e   Mita, Alain C ^f   Yung, Lotus ^a   Bryan, Peter ^a   McNally, Richard ^a   Renschler, Markus F ^a   Sharma, Sunil ^g  

^a CELGENE CORPORATION   (United States)

^b Sarcoma Oncology Center   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e SINAI HOSPITAL OF BALTIMORE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF UTAH   (United States)

Author keywords

Advanced solid tumors; Amrubicin; Anthracyclines; Cardiac effects; Pharmacokinetics

Indexed keywords

AMRUBICIN; AMRUBICINOL; DRUG METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; NQO1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; ERYTHROCYTE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; HEART RATE VARIABILITY; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAD(P)H:QUINONE OXIDOREDUCTASE 1 GENE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; QT INTERVAL; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; ELECTROCARDIOGRAPHY; GENETICS; HEART; HEART RATE; MIDDLE AGED; NEOPLASM; PHYSIOLOGY;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS;

MLCS; MLOWN;

EID: 84878827717     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2093-1     Document Type: Article

References (27)

1. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238 (Pubitemid 29008005)
2. Morisada S, Yanagi Y, Nogushi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69-76 (Pubitemid 20027201)
3. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073 (Pubitemid 28544784)
4. Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109-4112 (Pubitemid 10030436)
5. Dessypris EN, Brenner DE, Baer MR, Hande KR (1988) Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia. Cancer Res 48:503-506 (Pubitemid 18056511)
6. Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30:51-57
7. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C et al (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598-2603
8. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF et al (2011) Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29:287-293
9. O'Brien M, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F et al (2011) Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive-stage small cell lung cancer - EORTC 08062. Eur J Cancer 47:2322-2330
10. Okamoto I, Hamada A, Matsunaga Y, Sasaki J, Fujii S, Uramoto H et al (2006) Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 57:282-288
11. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K et al (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401-5406
12. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H et al (2006) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448-5453 (Pubitemid 46623179)
13. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y et al (2005) Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16:430-436 (Pubitemid 40458320)
14. Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H et al (2006) Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 28:76-82 (Pubitemid 44391698)
15. Makino Y, Yamamoto N, Sato H, Ando R, Goto Y, Tanai C et al (2012) Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. Cancer Chemother Pharmacol 69:861-869
16. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB et al (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784
17. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15:219-225 (Pubitemid 27453876)
18. Noda T, Wanatabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128 (Pubitemid 28495213)
19. Spigel DR, Von Pawel J, Jotte R, Socinski MA, O'Brien ME, McNally R et al (2011) Cardiac safety of amrubicin in a randomized phase 3 trial of amrubicin vs topotecan as second-line treatment for small cell lung cancer (SCLC) [Abstract O09.01]. J Thorac Oncol 6(Suppl 2):S309
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996) ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 10 June 1996. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1--Guideline.pdf. Accessed 14 June 2012
21. Inoue K, Ogawa M, Horikoshi N, Mukaiyama T, Itoh Y, Imajoh K et al (1989) Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Invest New Drugs 7:213-218 (Pubitemid 19202362)
22. Schrijvers D (2003) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 42:779-791 (Pubitemid 36995081)
23. Tani N, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 35:1121-1133 (Pubitemid 43163250)
24. Takakuwa O, Oguri T, Ozasa H, Uemura T, Kunii E, Kasai D et al (2011) C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin. J Thorac Oncol 6:1826-1832
25. Guidance for Industry (2005) E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf. Accessed 14 June 2012
26. Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL (2008) Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin Pharmacol 48:215-224
27. Jotte R, Von Pawel J, Spigel DR, Socinski MA, O'Brien M, Paschold EH et al (2011) Randomized phase III trial of amrubicin versus topotecan (topo) as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol 29(Suppl):7000 [abstract]